Literature DB >> 12562686

Impact of clade diversity on HIV-1 virulence, antiretroviral drug sensitivity and drug resistance.

Shalom Spira1, Mark A Wainberg, Hugues Loemba, Dan Turner, Bluma G Brenner.   

Abstract

HIV-1 infection is characterized by genetic diversity wherein distinct viral subtypes (clades A, B, C, D, E, F, G, K and O) are expanding in different geographical regions. This article deals with the topic of HIV-1 subtype diversity in the context of sensitivity to antiretroviral drugs, drug resistance and viral fitness. Increasing evidence suggests that all clades of HIV probably display similar sensitivity to antiviral drugs. However, viruses from some subtypes and/or geographical regions may have a greater propensity to develop resistance against certain drugs than do other viral variants. In addition, differences in regard to replication capacity or fitness may exist among various HIV subtypes and differences in this regard may potentially become magnified under conditions of drug resistance. Immunological pressures may also play an important role in the evolution of viral subtypes that may impact on ultimate drug resistance profiles.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12562686     DOI: 10.1093/jac/dkg079

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  75 in total

1.  The effect of clade-specific sequence polymorphisms on HIV-1 protease activity and inhibitor resistance pathways.

Authors:  Rajintha M Bandaranayake; Madhavi Kolli; Nancy M King; Ellen A Nalivaika; Annie Heroux; Junko Kakizawa; Wataru Sugiura; Celia A Schiffer
Journal:  J Virol       Date:  2010-07-21       Impact factor: 5.103

2.  Molecular detection, epidemiology, and genetic characterization of novel European field isolates of equine infectious anemia virus.

Authors:  Katia Cappelli; Stefano Capomaccio; Frank R Cook; Michela Felicetti; Maria Luisa Marenzoni; Giacomo Coppola; Andrea Verini-Supplizi; Mauro Coletti; Fabrizio Passamonti
Journal:  J Clin Microbiol       Date:  2010-11-17       Impact factor: 5.948

3.  Δ20 IFITM2 differentially restricts X4 and R5 HIV-1.

Authors:  Wan-Lin Wu; Christopher Robert Grotefend; Ming-Ting Tsai; Yi-Ling Wang; Vladimir Radic; Hyungjin Eoh; I-Chueh Huang
Journal:  Proc Natl Acad Sci U S A       Date:  2017-06-19       Impact factor: 11.205

4.  Evaluation of a real-time nucleic acid sequence-based amplification assay using molecular beacons for detection of human immunodeficiency virus type 1.

Authors:  D R McClernon; C Vavro; M St Clair
Journal:  J Clin Microbiol       Date:  2006-06       Impact factor: 5.948

5.  Effects of antifungal interventions on the outcome of experimental infections with phenotypic switch variants of Cryptococcus neoformans.

Authors:  Bettina C Fries; Emily Cook; Xiabo Wang; Arturo Casadevall
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

6.  Structural and functional studies of CCAAT/enhancer binding sites within the human immunodeficiency virus type 1 subtype C LTR.

Authors:  Yujie Liu; Michael R Nonnemacher; Devin L Stauff; Luna Li; Anupam Banerjee; Bryan Irish; Evelyn Kilareski; Nirmala Rajagopalan; Joyce B Suchitra; Zafar K Khan; Udaykumar Ranga; Brian Wigdahl
Journal:  Biomed Pharmacother       Date:  2010-09-25       Impact factor: 6.529

7.  In vitro antiretroviral activity and in vitro toxicity profile of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor for treatment of human immunodeficiency virus infection.

Authors:  Z Gu; B Allard; J M de Muys; J Lippens; R F Rando; N Nguyen-Ba; C Ren; P McKenna; D L Taylor; R C Bethell
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

Review 8.  Human immunodeficiency virus type 1 vaccine development: recent advances in the cytotoxic T-lymphocyte platform "spotty business".

Authors:  Kimberly A Schoenly; David B Weiner
Journal:  J Virol       Date:  2007-11-07       Impact factor: 5.103

Review 9.  Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: pathogenetic and therapeutic implications.

Authors:  L Buonaguro; M L Tornesello; F M Buonaguro
Journal:  J Virol       Date:  2007-07-18       Impact factor: 5.103

10.  Neruodevelopmental Outcomes in Preschool Children Living With HIV-1 Subtypes A and D in Uganda.

Authors:  Horacio Ruiseñor-Escudero; Alla Sikorskii; Itziar Familiar-Lopez; Deborah Persaud; Carrie Ziemniak; Noeline Nakasujja; Robert Opoka; Michael Boivin
Journal:  Pediatr Infect Dis J       Date:  2018-12       Impact factor: 2.129

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.